Please ensure Javascript is enabled for purposes of website accessibility

Aleafia Health Sets Q3 Results Release Date

By Eric Volkman - Updated Oct 24, 2019 at 9:19AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Atypically for a marijuana stock, the company is forecasting a net profit for the period.

Alefia Health (ALEAF -7.85%) has fixed a date for its next quarterly earnings release.

The company announced that it will reveal its third quarter of fiscal 2019 results before market open on Tuesday, Nov. 12. On that day starting at 8:30 a.m. EDT, Aleafia will host a conference call to discuss its performance during the quarter, which ended on Sept. 30. CEO Geoffrey Benic and CFO Benjamin Ferdinand will lead the call.

Marijuana plant in growing facility.

Image source: Getty Images.

This will be a high-stakes quarter for the company. In late September, Aleafia proffered guidance for the quarter, which it is forecasting to be the first net profit in its history. This would represent not only a high-water mark for the company but a rarity among marijuana stocks as a class. Burdened by negative external (supply challenges, to name but one) and internal factors (for instance poor management), cannabis companies frequently and commonly book quarterly net losses.

The positive news was somewhat tempered by the fact that Aleafia did not put a number or even a range on that anticipated net profit. It also didn't offer any number(s) for revenue. It did assert that Q3 "will mark our second consecutive quarter featuring both substantial expense reductions and increased revenues as we continue to drive toward sustainable, compliant growth that will deliver real benefits to our stakeholders."

In that brief guidance note, Aleafia also said it is effectively shifting its business model. "We have, until now been executing on major capital projects which are now either finished or weeks away from completion," the company wrote. "With a strong cash position, we are extremely well positioned to build on the growth experienced this quarter [Q3] on a much greater scale."

Aleafia said its balance sheet is strong, bolstered by roughly $51 million in cash.

Although not as acquisitive as some of its larger rivals, the company has made a number of asset purchases. The one with arguably the most potential is its late 2018 acquisition of, and subsequent merger with, vertically integrated cannabis company Emblem Health in an all-stock deal. That once-independent business is now a fully owned subsidiary of Aleafia.

Emblem was in the news recently, as a supply deal it signed as a stand-alone company with Aphria (APHA) was terminated by Aleafia earlier this month. In its press release on the matter, Aleafia wrote bluntly of Aphria's "failure to meet its supply obligations" under a contract in which Aphria was to supply up to 175,000 kilos worth of cannabis product to Emblem across a five-year period.  


Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aleafia Health Inc. Stock Quote
Aleafia Health Inc.
$0.05 (-7.85%) $0.00
Aphria Stock Quote

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.